A dramatic fetal outcome following transplacental transfer of dasatinib

Cortes, 2004, Natural history and staging of chronic myelogenous leukemia., Hematol Oncol Clin North Am, 18, 569, 10.1016/j.hoc.2004.03.011

Jabbour, 2011, Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia., Cancer, 117, 1800, 10.1002/cncr.25717

Apperley, 2009, Issues of imatinib and pregnancy outcome., J Natl Compr Canc Netw, 7, 1050, 10.6004/jnccn.2009.0069

Pye, 2008, The effects of imatinib on pregnancy outcome., Blood, 111, 5505, 10.1182/blood-2007-10-114900

Cole, 2009, Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature., Clin Lymphoma Myeloma, 9, 324, 10.3816/CLM.2009.n.064

He, 2008, Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats., Drug Metab Dispos, 36, 2564, 10.1124/dmd.108.022764

Kroll, 2010, Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib., Leuk Lymphoma, 51, 1751, 10.3109/10428194.2010.497982

Conchon, 2009, Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study., J Hematol Oncol, 2, 42, 10.1186/1756-8722-2-42

Hochhaus, 2008, Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib., Leukemia, 22, 1200, 10.1038/leu.2008.84

OHare, 2005, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants., Cancer Res, 65, 4500, 10.1158/0008-5472.CAN-05-0259

Kantarjian, 2010, Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia., N Engl J Med, 362, 2260, 10.1056/NEJMoa1002315